TC Biopharm (Holdings) Plc (NASDAQ:TCBP – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 48,500 shares, a decline of 62.3% from the April 30th total of 128,500 shares. Based on an average trading volume of 319,000 shares, the days-to-cover ratio is currently 0.2 days.
Analyst Ratings Changes
Separately, HC Wainwright lowered their price objective on shares of TC Biopharm from $9.00 to $7.00 in a report on Thursday, April 27th.
TC Biopharm Trading Up 1.2 %
Shares of TCBP traded up $0.01 during mid-day trading on Friday, reaching $0.87. The company’s stock had a trading volume of 166,631 shares, compared to its average volume of 884,363. TC Biopharm has a 52 week low of $0.71 and a 52 week high of $41.48. The company’s fifty day moving average price is $1.53 and its two-hundred day moving average price is $3.85.
Institutional Investors Weigh In On TC Biopharm
TC Biopharm Company Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19.
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBP)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.